Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb 17:2011:708404.
doi: 10.4061/2011/708404.

Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease

Affiliations

Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease

Isidro Ferrer. Parkinsons Dis. .

Abstract

Parkinson disease (PD) is no longer considered a complex motor disorder characterized by Parkinsonism but rather a systemic disease with variegated non-motor deficits and neurological symptoms, including impaired olfaction, autonomic failure, cognitive impairment, and psychiatric symptoms. Many of these alterations appear before or in parallel with motor deficits and then worsen with disease progression. Although there is a close relation between motor symptoms and the presence of Lewy bodies (LBs) and neurites filled with abnormal α-synuclein, other neurological alterations are independent of the amount of α-synuclein inclusions in neurons and neurites, thereby indicating that different mechanisms probably converge in the degenerative process. Involvement of the cerebral cortex that may lead to altered behaviour and cognition are related to several convergent factors such as (a) abnormal α-synuclein and other proteins at the synapses, rather than LBs and neurites, (b) impaired dopaminergic, noradrenergic, cholinergic and serotoninergic cortical innervation, and (c) altered neuronal function resulting from reduced energy production and increased energy demands. These alterations appear at early stages of the disease and may precede by years the appearance of cell loss and cortical atrophy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Forno LS. Neuropathology of Parkinson’s disease. Journal of Neuropathology and Experimental Neurology. 1996;55(3):259–272. - PubMed
    1. Jellinger K, Mizuno Y. Parkinson's disease. In: Dickson D, editor. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel, Switzerland: ISN Neuropathol Press; 2003. pp. 159–187.
    1. Braak H, Sandmann-Keil D, Gai W, Braak E. Extensive axonal Lewy neurites in Parkinson’s disease: a novel pathological feature revealed by α-synuclein immunocytochemistry. Neuroscience Letters. 1999;265(1):67–69. - PubMed
    1. Dickson DW. α-Synuclein and the Lewy body disorders. Current Opinion in Neurology. 2001;14(4):423–432. - PubMed
    1. Goedert M. Parkinson’s disease and other α-synucleinopathies. Clinical Chemistry and Laboratory Medicine. 2001;39(4):308–312. - PubMed